Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Svelte Medical Systems (Svelte) has initiated the European clinical trial at the Thoraxcenter Research Center in Rotterdam, the Netherlands, for its Stent-on-a-Wire (SOAW) cobalt–chromium bare metal stent. The SOAW delivery system represents a more deliverable, very low profile system that can reduce procedural costs and can potentially lower the rate of stent thrombosis.
Subscribe to our email newsletter
The company also plans to introduce its drug eluting stent (DES) with non-inflammatory properties instead of utilising typical polymeric coatings, which are known to irritate the vessel lining. Svelte Medical anticipates receiving CE Mark for the first generation bare metal SOAW by the middle of 2010 and plans to initiate clinical activities for the DES in 2011.
Furthermore, the company has appointed Tim Shannon, former president of Mentice as the vice president of worldwide sales and marketing and Michael Johnson, former managing director and CFO of JP Morgan Chase, as the CFO and treasurer of the organisation.
Mark Pomeranz, president and CEO of Svelte, said: “We are extremely pleased to announce such significant news at Svelte. The initiation of our clinical trial enhances our track record of delivering on strategic milestones and the addition of Mr Shannon and Mr Johnson rounds out the final pieces of the management team which will drive the company’s growth moving forward.”